Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-05-04
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well eribulin mesylate works in treating patients with
previously treated breast cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading.